MOTS-c vs SS-31: Two Opposite Strategies for the Mitochondrion
Last updated
MOTS-c and SS-31 both carry the label mitochondrial peptide, and that label hides the most instructive contrast in the catalog: one is a message the mitochondrion sends, the other is a molecule sent to the mitochondrion. This page compares the two research compounds by mechanism, published evidence and documentation, strictly from a laboratory perspective. Nothing here is medical advice.
What are MOTS-c and SS-31?
MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome itself, in the 12S rRNA region, one of the founding members of the mitochondrial-derived peptide class. It functions as retrograde signalling: information travelling from the mitochondrion outward, including, under metabolic stress, translocation of the peptide to the cell nucleus where it regulates nuclear gene expression.
SS-31, also known as elamipretide, is a synthetic Szeto-Schiller tetrapeptide designed in the opposite direction: administered externally, it concentrates selectively in the inner mitochondrial membrane, where it binds cardiolipin, the phospholipid that holds cristae structure and the electron transport chain complexes in working order.
How do their mechanisms differ?
The cleanest way to hold the difference is signal versus structure. MOTS-c operates as an information molecule: the published work links it to AMPK signalling, glucose homeostasis and, in the 2021 exercise study, to age-dependent physical decline in mouse models, with expression rising after exercise in human muscle. SS-31 operates as a physical stabiliser: by binding cardiolipin it is reported to reduce electron leak, limit reactive oxygen species generation and preserve ATP production efficiency in stressed mitochondria. One changes what the cell decides; the other changes what the organelle can physically do.
What does the published evidence show?
MOTS-c has an early-stage but fast-growing literature: discovery and mechanism papers, the exercise physiology work, and early human pharmacokinetic reports, with independent replication still accumulating. SS-31 has the deeper development history of the two: alongside a broad preclinical literature across cardiac, renal, muscular and neural injury models, elamipretide has advanced through clinical trial programmes in mitochondrial conditions. The research material supplied as SS-31 is not that investigational or medicinal product, and no EU marketing authorisation exists for either compound.
| MOTS-c | SS-31 (elamipretide) | |
|---|---|---|
| Origin | Encoded in mitochondrial DNA | Fully synthetic tetrapeptide |
| Direction | Signal outward from the mitochondrion | Delivered inward to the membrane |
| Reported mechanism | AMPK signalling, nuclear gene regulation | Cardiolipin binding, cristae stabilisation |
| Evidence base | Early, growing, preclinical plus early human data | Broad preclinical plus clinical programmes |
| EU marketing authorisation | None | None |
Which research applications does each suit?
The mechanisms sort the applications. MOTS-c belongs in studies of metabolic signalling, exercise biology, mitochondrial-nuclear communication and ageing models, anywhere the question is how mitochondrial state is communicated. SS-31 belongs in studies of membrane biology, oxidative stress, ischaemia-reperfusion and bioenergetics, anywhere the question is how mitochondrial function can be preserved under load. Used together, the pair lets a laboratory probe both the information layer and the hardware layer of the same organelle, which is why they appear side by side in mitochondrial research programmes.
What is the regulatory status?
Neither compound has an EU marketing authorisation. Elamipretide has been in formal clinical development, which makes the distinction sharper, not softer: research material supplied under a research use only framework is not a medicine, not that clinical product, and not for human or veterinary use. Neither compound is currently named on the WADA Prohibited List; the live list is the binding reference for athletes.
Research sourcing and quality checks
Both compounds are available in our catalog as research reagents: MOTS-c and SS-31. Where a batch has been tested, its report is published in the lab reports archive and linked from the product page. SS-31 contains a non-standard amino acid, which makes mass spectrometry identity data the meaningful line on its certificate; what to check is covered in our guide on reading a certificate of analysis, and the wider context sits in our evidence-tier ranking.
Conclusion
Signal versus structure is the whole comparison: MOTS-c is the mitochondrion talking, SS-31 is the laboratory talking back. The two are not alternatives for any single experimental question, and that is precisely their value as a pair. Evidence-wise, SS-31 brings the deeper development history, MOTS-c the younger and faster-moving literature, and both reward the same discipline: read the primary papers, and match the tool to the layer of biology under study.
References
- MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus. BioEssays 2019. PubMed
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Nat Commun 2021. PubMed
- Mitochondrial Cardiolipin-Targeted Tetrapeptide SS-31, neuroprotective effects. 2025. PubMed
- Targeting Mitochondrial Dysfunction With Elamipretide (SS-31), skeletal muscle. 2026. PubMed